期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 184, 期 2, 页码 242-245出版社
WILEY
DOI: 10.1111/bjh.15560
关键词
Waldenstrom macroglobulinaemia; TP53; CXCR4; MYD88; ibrutinib
类别
Little is known about TP53 mutations in Waldenstrom Macroglobulinaemia (WM). We evaluated 265 WM patients for TP53 mutations by next-generation sequencing, and validated the findings by Sanger sequencing. TP53 mutations were identified and validated in 6 (2 center dot 6%) patients that impacted the DNA-binding domain. All six were MYD88- and CXCR4-mutated. Ibrutinib showed activity in patients carrying all three mutations. With a median follow-up of 18 months, 2 (33%) with biallelic TP53 inactivation died of progressive disease. TP53 mutations are rare in WM, and associate with MYD88 and CXCR4 mutations. WM patients with TP53 mutations show response to ibrutinib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据